DE69222306D1 - Oral verabreichbare therapeutische proteine und herstellungsverfahren - Google Patents

Oral verabreichbare therapeutische proteine und herstellungsverfahren

Info

Publication number
DE69222306D1
DE69222306D1 DE69222306T DE69222306T DE69222306D1 DE 69222306 D1 DE69222306 D1 DE 69222306D1 DE 69222306 T DE69222306 T DE 69222306T DE 69222306 T DE69222306 T DE 69222306T DE 69222306 D1 DE69222306 D1 DE 69222306D1
Authority
DE
Germany
Prior art keywords
protein
therapeutic protein
oral
production method
stabilizing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69222306T
Other languages
English (en)
Other versions
DE69222306T2 (de
Inventor
Jacob G Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of DE69222306D1 publication Critical patent/DE69222306D1/de
Application granted granted Critical
Publication of DE69222306T2 publication Critical patent/DE69222306T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69222306T 1991-06-21 1992-06-11 Oral verabreichbare therapeutische proteine und herstellungsverfahren Expired - Fee Related DE69222306T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71916091A 1991-06-21 1991-06-21
PCT/US1992/005004 WO1993000077A1 (en) 1991-06-21 1992-06-11 Orally administrable therapeutic proteins and method of making

Publications (2)

Publication Number Publication Date
DE69222306D1 true DE69222306D1 (de) 1997-10-23
DE69222306T2 DE69222306T2 (de) 1998-04-09

Family

ID=24888975

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69222306T Expired - Fee Related DE69222306T2 (de) 1991-06-21 1992-06-11 Oral verabreichbare therapeutische proteine und herstellungsverfahren

Country Status (11)

Country Link
US (4) US5609871A (de)
EP (1) EP0590060B1 (de)
JP (1) JPH06508371A (de)
AT (1) ATE158180T1 (de)
AU (1) AU664561B2 (de)
CA (1) CA2110899C (de)
DE (1) DE69222306T2 (de)
DK (1) DK0590060T3 (de)
ES (1) ES2109362T3 (de)
GR (1) GR3025628T3 (de)
WO (1) WO1993000077A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
DE69305313T3 (de) † 1992-12-22 2001-06-21 Univ Cincinnati Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5551058A (en) * 1994-10-31 1996-08-27 Motorola, Inc. Method and system for intelligent cell selection using location data in cellular systems
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US6605276B1 (en) * 1995-05-09 2003-08-12 University Of Medicine & Dentistry Of New Jersey Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
JP2000509146A (ja) * 1996-04-12 2000-07-18 オンコール，インコーポレーテッド 遅延クエンチングによりホルムアルデヒド固定を制御する方法および組成物
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
DE19854749A1 (de) * 1998-11-27 2000-05-31 Privates Inst Bioserv Gmbh Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen
BR9915771A (pt) * 1998-11-30 2001-12-26 Cytos Biotechnology Ag Apresentação molecular ordenada de antìgenos,processo de preparação e utilização
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
AU1267501A (en) * 1999-09-07 2001-04-10 Bioserv Ag Novel autogenous vaccines used to obtain an immune tolerance
US6500462B1 (en) * 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
WO2001051008A2 (en) * 2000-01-07 2001-07-19 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
JP4344136B2 (ja) 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
US6932861B2 (en) * 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US20060040899A1 (en) * 2000-12-15 2006-02-23 Hassan Jomaa Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies
AU2002314967B2 (en) * 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
EP1463527A4 (de) * 2001-10-04 2005-05-11 Protein Therapeutics Inc Verwendung von gammaglobulin zur behandlung von immunvermittelten krankheiten
US20030091637A1 (en) * 2001-10-15 2003-05-15 Hans-Ulrich Petereit Use of a copolymer to prepare a pharmaceutical form that contains a peptide of protein as active principle
EP1507554B1 (de) 2002-05-10 2011-08-10 Agennix Incorporated Lactoferrin bei der behandlung maligner neoplasien und anderer hyperproliferativer erkrankungen
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
AU2003273206B2 (en) * 2002-05-31 2009-08-20 Children's Hospital Medical Center Method, composition and kit for antigenic binding of Norwalk-Like viruses
EP2298338B1 (de) 2002-09-16 2012-08-22 Agennix Incorporated Lactoferrin-Zusammenfassungen und Verfahren zur Behandlung von Hautwunden
EP2891666B1 (de) 2002-10-16 2017-06-28 Purdue Pharma L.P. Antikörper, die an zellassoziiertes CA 125/O722P binden, und Verfahren zu deren Anwendung
EP1558650A2 (de) 2002-11-08 2005-08-03 Ablynx N.V. Antikörper aus camelidae gegen immunoglobulin e und ihre verwendung zur behandlung allergischer erkrankungen
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
AU2004229462A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
RU2362560C2 (ru) * 2003-04-08 2009-07-27 Проджиникс Фармасьютикалз, Инк. Фармацевтическая препаративная форма
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
EP2591786B1 (de) 2003-10-16 2017-04-12 Cancure Limited Immunmodulierende Zusammensetzungen und ihre Verwendung
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
US20080107601A1 (en) * 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
PT1883665T (pt) 2005-04-22 2017-11-14 Univ Geneve Composições polilactídeo e usos das mesmas
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
EP1888640B1 (de) 2005-05-18 2012-03-14 Ablynx N.V. Verbesserte nanokörper gegen tumornekrosefaktor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP2049135A4 (de) 2006-06-22 2009-12-30 Agennix Inc Lactoferrin als radioprotektives mittel
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20110152263A1 (en) * 2006-11-16 2011-06-23 Xi Jiang Composition and method for inhibiting norovirus infection
EP3103451A1 (de) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targeting des ncca-atp-kanals für organschutz nach einer ischämischen episode
CN101674730B (zh) 2007-02-02 2014-09-10 贝勒医学院 用于治疗代谢疾病的组合物和方法
US20100305323A1 (en) 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
CA2682550C (en) * 2007-03-29 2016-05-17 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN107011445B (zh) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
WO2009099411A1 (en) * 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2306829B1 (de) 2008-07-01 2017-01-04 University of Chicago Partikel, die einen peripheren opioidrezeptorantagonisten enthalten
EP2719380A3 (de) 2008-09-16 2014-07-30 University of Maryland, Baltimore SUR1-Hemmer für therapeutische Zwecke
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
ES2702049T3 (es) 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
CN107043408B (zh) 2009-06-09 2021-02-09 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
WO2011104352A1 (en) 2010-02-25 2011-09-01 Agennix Ag Oral lactoferrin in the treatment of severe sepsis
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
US10865445B2 (en) 2010-08-18 2020-12-15 Fred Hutchinson Cancer Research Center Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN105541978B (zh) 2010-09-15 2019-12-13 兰德尔·J·米斯尼 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法
WO2012053976A1 (en) 2010-10-18 2012-04-26 Agency For Science, Technology And Research Use of exosomes to promote or enhance hair growth
WO2012070971A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Косметологическая и фармацевтическая композиция для омоложения и восстанов- ления кожи, в том числе после хирургических операций
AU2012287120B2 (en) 2011-07-22 2017-02-23 The University Of Chicago Treatments for migraine and related disorders
US9655905B2 (en) 2011-09-14 2017-05-23 King Abdullah University Of Science And Technology Treatment of sickle cell disease
WO2013041969A2 (en) 2011-09-21 2013-03-28 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US10208012B2 (en) 2013-03-13 2019-02-19 Board Of Regents, The University Of Texas System Compounds for treating inflammatory and hyperproliferative diseases
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
US10328127B2 (en) 2013-12-02 2019-06-25 Baylor College Of Medicine Methods for stimulation of appetite and increase in weight by administration of asprosin
IL247301B (en) * 2014-02-20 2022-07-01 Vaxart Inc Formulations for administration to the small intestine
CN106460050A (zh) * 2014-04-28 2017-02-22 西格马-奥尔德里奇有限责任公司 使用靶向核酸内切酶进行哺乳动物基因组的表观遗传修饰
US10624955B2 (en) 2014-05-07 2020-04-21 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US10278986B2 (en) 2014-08-14 2019-05-07 The Regents Of The University Of Colorado, A Body Corporate Antibody-siRNA conjugates and uses therefor
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
EP3206491B1 (de) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Verwendung von methylnaltrexon zur verringerung der tumorprogression
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR101708200B1 (ko) 2015-03-24 2017-03-08 아우토리브 디벨롭먼트 아베 차량용 커튼 에어백
US11285190B2 (en) 2015-04-20 2022-03-29 The Board Of Regents Of The University Of Texas System CLEC11a is a bone growth agent
KR20240031420A (ko) * 2015-06-12 2024-03-07 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
WO2016205615A1 (en) 2015-06-17 2016-12-22 The Johns Hopkins University Tdp-43 in degenerative disease
KR20240042137A (ko) 2015-07-24 2024-04-01 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
EA034582B1 (ru) 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
DK3331902T3 (da) 2015-08-07 2021-07-26 Alx Oncology Inc Konstruktioner med et sirp-alpha-domæne eller en variant deraf
WO2017132321A1 (en) 2016-01-29 2017-08-03 The Johns Hopkins University Novel inhibitors of bacterial growth
WO2017143112A2 (en) 2016-02-17 2017-08-24 The Johns Hopkins University An oxazolidinone for treatment of infections with mycobacterium tuberculosis
WO2017147370A1 (en) 2016-02-24 2017-08-31 The Johns Hopkins University Novel antiviral proteins and their uses in therapeutic methods
WO2017155935A1 (en) 2016-03-07 2017-09-14 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
BR112018068055A2 (pt) 2016-03-10 2019-01-08 Univ Johns Hopkins métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
JP2019510088A (ja) 2016-03-17 2019-04-11 ザ ジョンズ ホプキンス ユニバーシティーＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Ｐａｒｉｓのファルネシル化によってパーキンソン病を予防または治療する方法
EP3436609B1 (de) 2016-03-30 2022-05-04 The Johns Hopkins University Olfr90-spezifität und nachweisverfahren
CA3019482A1 (en) 2016-03-31 2017-10-05 Vhsquared Limited Compositions
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
CN109641048A (zh) 2016-07-22 2019-04-16 格利克尼克股份有限公司 产生具有增强的Fc受体结合的经有序多聚化的免疫球蛋白Fc组合物的人蛋白片段的融合蛋白
EP3295956A1 (de) 2016-09-20 2018-03-21 Biomay Ag Polypeptidkonstrukt mit fragmenten von allergenen
US11149275B2 (en) 2016-10-10 2021-10-19 The Johns Hopkins University Device and method to treat esophageal disorders
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
CN110381991B (zh) 2017-03-28 2024-04-09 儿童医院医学中心 诺如病毒s颗粒类疫苗及其制备和使用方法
WO2019014044A1 (en) 2017-07-12 2019-01-17 The Johns Hopkins University ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
EP3459528B1 (de) 2017-09-20 2022-11-23 Tillotts Pharma Ag Herstellung von festen darreichungsformen mit antikörpern durch lösungs-/suspensionsschichtung
WO2019118527A1 (en) 2017-12-14 2019-06-20 The Johns Hopkins University Novel anti-fungal inhibitors
EP3762009B1 (de) 2018-03-08 2022-05-11 Applied Molecular Transport Inc. Von toxinen abgeleitete konstrukte zur oralen verabreichung
PT3762009T (pt) 2018-03-08 2022-08-22 Applied Molecular Transport Inc Construções de administração derivadas de toxinas para administração oral
EP3921029A4 (de) 2019-02-07 2022-12-07 Baylor College of Medicine Periostale skelettstammzellen bei der knochenreparatur
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
JP2022538083A (ja) 2019-06-21 2022-08-31 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
JP2022537780A (ja) 2019-06-21 2022-08-29 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
EP3844169A4 (de) 2019-08-16 2021-12-15 Applied Molecular Transport Inc. Zusammensetzungen, formulierungen und interleukinherstellung und -reinigung

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
LU76538A1 (de) * 1977-01-07 1978-09-18
US4469677A (en) * 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5230888A (en) * 1982-05-06 1993-07-27 Massachusetts Institute Of Technology Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0192321A3 (de) * 1985-01-19 1987-09-02 Beecham Group Plc Allergene enthaltende Arzneimittel mit magensaftresistentem Überzug
CH663900A5 (de) * 1985-05-06 1988-01-29 Cernitin Sa Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
JPH0759496B2 (ja) * 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
DE3777658D1 (de) * 1986-08-28 1992-04-23 Enzacor Pty Ltd Tierwachstumserreger.
FR2609895B1 (fr) * 1987-01-28 1991-06-28 Bruttmann Georges Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPS6417A (en) * 1987-02-20 1989-01-05 Shikoku Chem Corp Chemotherapeutic agent composition
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
JPH04504122A (ja) * 1989-03-17 1992-07-23 ピットマン―ムーア・インコーポレイテッド 巨大分子タンパク質の制御放出考案物
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
KR0140841B1 (ko) * 1990-10-15 1998-06-01 조앤 월리스 자기항원의 경구 투여에 의한 자기면역 질병의 치료
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
DE69305313T3 (de) * 1992-12-22 2001-06-21 Univ Cincinnati Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen

Also Published As

Publication number Publication date
EP0590060A4 (en) 1994-05-25
ES2109362T3 (es) 1998-01-16
EP0590060B1 (de) 1997-09-17
AU2249692A (en) 1993-01-25
DE69222306T2 (de) 1998-04-09
CA2110899C (en) 2006-08-08
DK0590060T3 (da) 1998-05-11
US5783193A (en) 1998-07-21
US6174529B1 (en) 2001-01-16
GR3025628T3 (en) 1998-03-31
US5629001A (en) 1997-05-13
AU664561B2 (en) 1995-11-23
WO1993000077A1 (en) 1993-01-07
US5609871A (en) 1997-03-11
JPH06508371A (ja) 1994-09-22
CA2110899A1 (en) 1993-01-07
ATE158180T1 (de) 1997-10-15
EP0590060A1 (de) 1994-04-06

Similar Documents

Publication Publication Date Title
DE69222306D1 (de) Oral verabreichbare therapeutische proteine und herstellungsverfahren
DK0603992T4 (da) Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
IS3644A7 (is) Aðferð til að framleiða lyfjablöndu á formi smápilla til að meðhöndla þarmabólgur
SE8001736L (sv) Indolerivat med terapeutisk verkan jemte sett for deras framstellning
RU95106976A (ru) Композиции для оральной вакцинации жвачных, способы их изготовления и способы вакцинирования жвачных
SE8505569D0 (sv) Enteralt preparat
FI862863A (fi) Foerfarande foer bindning av mikroflora och preparat foer detsamma.
NO995236L (no) Nerve-vekstfaktor som vaksine-adjuvant
NO982904D0 (no) Oral farmas°ytisk sammensetning inneholdende 5-ASA, med modifisert frigj°ring, og fremgangsmÕte for behandling av tarmsykdommer
JPS5837285B2 (ja) チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JP3854657B2 (ja) 腸管保護剤
HK1003979A1 (en) Chemically modified allergens and process for the preparation thereof
IE35321B1 (en) Rearing pigs
FR2618439B1 (fr) Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
JP2001342127A (ja) 腸吸収性抗炎症因子含有免疫性物質及びその応用
RU2000104571A (ru) Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят
EA200200687A1 (ru) Композиция для усиления пролиферативного ответа в процессе адаптации желудочно-кишечного тракта и применения при синдроме укороченной тонкой кишки
RU93009804A (ru) Вакцина против эшерихиоза животных
RU93000004A (ru) Вещество для лечения подкожной фибрасаркомы и способ его получения
O'Brien et al. Enterotoxic diseases due to Salmonella and Shigella.
RU2000126729A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
RU97117569A (ru) Гастроветин
RU94041584A (ru) Способ лечения язвенной болезни
RU95101369A (ru) Противоязвенное средство

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee